Day One (DAWN) Soars 100% on $2.5-Billion Merger
Under the agreement, all issued and outstanding shares of Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc. (DAWN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vestal Point Capital Ryan Wilder | 5,200,000 | $48,464,000 | +95% | 1.65% |
| 2. | Deerfield Management James E. Flynn | 3,723,131 | $34,699,581 | -21% | 0.44% |
| 3. | AIGH Investment Partners Orin Hirschman | 1,992,021 | $18,565,635 | +32% | 4.49% |
| 4. | Hudson Bay Capital Management Sander Gerber | 1,700,000 | $15,844,000 | +29% | 0.05% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 1,489,924 | $13,886,092 | +8% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.97 | 111,387 | $1,110,907.11 | 12,929,322 | 2023-10-20 | Filing | |
| $10.06 | 384,400 | $3,867,371.52 | 12,817,935 | 2023-10-19 | Filing | |
| $10.21 | 979,667 | $10,000,048.87 | 12,433,535 | 2023-10-18 | Filing | |
| $13.00 | 769,230 | $9,999,990.00 | 11,453,868 | 2023-06-09 | Filing | |
| $15.00 | 766,667 | $11,500,005.00 | 766,667 | 2022-06-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.60 | 5,814 | $67,447.63 | 60,157 | 2026-02-17 | Filing | |
| $11.60 | 6,395 | $74,187.76 | 72,694 | 2026-02-17 | Filing | |
| $11.60 | 6,065 | $70,359.46 | 312,025 | 2026-02-17 | Filing | |
| $11.60 | 15,459 | $179,338.31 | 204,603 | 2026-02-17 | Filing | |
| $11.60 | 2,728 | $31,647.26 | 4,397 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,812 | $339,167 | 0% | |
| 2. | 750 | $16,080 | 0.01% | |
| 3. | 742 | $15,908 | 0% | |
| 4. | 640 | $13,722 | 0% | |
| 5. | 586 | $12,564 | 0% |
News See All
10 Stocks Investors Are Watching Closely This Week
In the fourth quarter alone, Samsara Inc. (NYSE:IOT) swung to a net income of $22 million, reversing a net loss of $11.2 million in the same quarter a year earlier.
Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger
In a joint statement, Day One Biopharmaceuticals Inc.
10 Stocks to Watch Right Now: Equinor, JD, Marvell and More
Ten stocks capped off Friday’s trading boasting strong gains, defying a market bloodbath, as investors took path from a flurry of strong corporate earnings and upbeat outlooks, among others.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2025 Earnings Call Transcript February 24, 2026Day One Biopharmaceuticals, Inc. misses on earnings expectations.
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib)
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2025 Earnings Call Transcript November 4, 2025Day One Biopharmaceuticals, Inc. beats earnings expectations.
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
H.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN)
With significant hedge fund interest and a share price under $10, Day One Biopharmaceuticals, Inc.
Hedge Fund Resource Center